Lilly Avoids Strattera Risk Management Program; QTc Key Concern In Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly’s response to an "approvable" letter for Strattera allowed the company to avoid a label requirement to test for poor metabolizers of the drug, as well as a related warning on QTc prolongation, review documents indicate.
You may also be interested in...
Abilify Review Shows FDA Debate Over QTc Methods Of Analysis
FDA’s review of Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify suggests that the method of analysis used to detect QT prolongation is key to the results.
Lilly Strattera Long-Term Efficacy Studies To Be Completed In 2003
Lilly expects to complete two postmarketing studies assessing long-term efficacy of its attention deficit/hyperactivity disorder drug Strattera by the end of 2003.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011